Annovis Bio Inc.

Annovis Bio Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapies for neurodegenerative diseases. The company's mission is to halt the death of nerve cells and restore brain health, offering new hope for millions of patients and their families affected by these debilitating conditions.

The company's primary focus is on its lead drug candidate, buntanetap (formerly ANVS401 or Posiphen), which is in clinical trials for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders such as Lewy body dementia and Alzheimer's in Down Syndrome. Buntanetap operates as a translational inhibitor of neurotoxic aggregating proteins (TINAPs), aiming to restore cellular homeostasis by modulating the production and clearance of disease-related proteins and improving axonal transport. This mechanism targets multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43. Annovis Bio's pipeline also includes ANVS405 for traumatic brain injury and stroke, and ANVS301 for cognitive enhancement in later stages of Alzheimer's disease.

Led by Founder, President, and CEO Dr. Maria L. Maccecchini, Annovis Bio has recently achieved several milestones. In April 2026, the company published Phase 2/3 Alzheimer's trial results for buntanetap in Nature NPJ Dementia, demonstrating cognitive improvements in early AD patients. Concurrently, Annovis Bio closed a $10 million public offering, securing funding to extend its cash runway through Q2 2027 for its Phase 3 Alzheimer's trial and New Drug Application submission. The company also secured a U.S. patent for buntanetap's use in preventing and treating neurological injuries from brain infections in March 2026, and an independent Data and Safety Monitoring Board approved the continuation of its pivotal Phase 3 AD clinical trial in February 2026. While Annovis Bio remains a clinical-stage company without marketable products, it distinguishes itself by developing a single drug that inhibits multiple neurotoxic proteins for both Alzheimer's and Parkinson's diseases.